Valion Bio, Inc. VBIO
3.03
(0.45)
(12.93%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow VBIO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(178.21%) | (93.69%) | (198.48%) | (489.30%) | |
| (156.02%) | (52.63%) | (66.64%) | (104.96%) | ||
ROIC |
(152.85%) | (26.95%) | (41.17%) | (61.01%) | |
Return on Tangible Assets |
(241.07%) | (36.22%) | (74.89%) | (153.07%) | |
Average Days of Receivables |
14.39 | — | — | — | |
Free Cash Flow per Share |
(115.34) | (164.07) | (96.84) | (108.54) | |
Free Cash Flow |
(6.09) | (7.58) | (11.17) | (14.67) | |
Capital Expenditures |
(0.01) | (0.58) | (0.04) | (0.10) | |
Piotroski F-Score |
2.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(67.22%) | (16.18%) | (34.05%) | (68.17%) | |
Accounts Receivable Turnover |
34.43 | — | — | — | |
Accounts Payable Turnover |
1.91 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
2.07 | — | 0.00 | 0.00 | |
Average Days of Payables |
222.74 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
1.92 | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
452.49% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
678.22% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
99.17% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.77 | 0.79 | 0.75 | |
Depreciation/Fixed assets |
22.92 | 0.01 | 0.06 | 0.15 | |
Capex/Depreciation |
(0.05) | (5.70) | (0.06) | (0.05) | |
Revenue per Share |
9.13 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(115.09) | (151.49) | (96.45) | (107.80) | |
Capex per Share |
(0.25) | (12.58) | (0.39) | (0.73) | |
Capex to Sales |
0.03 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(1,557.47%) | 0.00% | 0.00% | 0.00% |
Columns are period end dates